Tag
Vutrisiran improves cardiac structure, function, and biomarkers, reducing mortality and cardiovascular events in transthyretin amyloid cardiomyopathy over 30 months.
A study identified a robust plasma multi-metabolite signature that predicts long-term all-cause mortality in participants from the PREDIMED trial and several US cohorts, providing new insights into metabolic biomarkers.
Combining CA125 with NT-proBNP significantly improves prediction of cardiovascular and all-cause mortality, as well as rehospitalization risk in patients with acute heart failure.
Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.
A phase 3 trial indicates that fMRI-detected CNS pain activation may predict which rheumatoid arthritis patients respond best to TNF inhibitor therapy.
New Alzheimer’s Association guidelines endorse blood-based biomarkers as diagnostic adjuncts, not standalone tests, emphasizing rigorous clinical evaluation and high test accuracy.
